61948-60-5

Basic information

• Product Name: 2,4-Dichloro-8-methoxyquinazoline
• Synonyms: 2,4-Dichloro-8-methoxyquinazoline;8-Methoxy-2,4-dichloroquinazoline;2,4-Dichloro-8-methoxyquizoline
• CAS NO: 61948-60-5
• Molecular Formula: C₉H₆Cl₂N₂O
• Molecular Weight: 229.06
• Product Categories: API intermediates
• Mol File: 61948-60-5.mol
• Article Data: 20

Chemical Properties

• Melting Point: 157-159 °C
• Boiling Point: 315.923 °C at 760 mmHg
• Flash Point: 144.865 °C
• Appearance: /
• Density: 1.450
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.638
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -0.84±0.30(Predicted)
• CAS DataBase Reference: 2,4-Dichloro-8-methoxyquinazoline(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-Dichloro-8-methoxyquinazoline(61948-60-5)
• EPA Substance Registry System: 2,4-Dichloro-8-methoxyquinazoline(61948-60-5)

Safety Data

• Hazardous Substances Data: 61948-60-5(Hazardous Substances Data)

Usage

Chemical Properties

White flocculent solid

Uses

2,4-Dichloro-8-methoxyquinazoline has been used as a reactant for the preparation of p97 ATPase inhibitors.

InChI:InChI=1/C9H6Cl2N2O/c1-14-6-4-2-3-5-7(6)12-9(11)13-8(5)10/h2-4H,1H3

Upstream product

• 62484-14-4 8-methoxy-1,2,3,4-tetrahydroquinazoline-2,4-dione 
• 3177-80-8 2-amino-3-methoxybenzoic acid 
• 4920-80-3 3-methoxy-2-nitrobenzoic acid 
• 62484-14-4 8-methoxyquinazoline-2,4-diol 

Downstream Products

• 1616598-73-2 C₂₃H₂₄FN₇O₂*C₂HF₃O₂ 
• 1616599-01-9 5-[(2,4-dimethoxybenzyl)amino]-7-methoxy[1,2,4]triazolo[1,5-c]quinazoline-2-carbaldehyde 
• 1616599-02-0 (±)-1-{5-[(2,4-dimethoxybenzyl)amino]-7-methoxy[1,2,4]triazolo[1,5-c]quinazolin-2-yl}ethanol 
• 1616599-03-1 (±)-1-{5-[(2,4-dimethoxybenzyl)amino]-7-methoxy[1,2,4]triazolo[1,5-c]quinazolin-2-yl}ethyl methanesulfonate 
• 1616599-04-2 (±)-2-(1-chloroethyl)-N-(2,4-dimethoxybenzyl)-7-methoxy[1,2,4]triazolo[1,5-c]quinazolin-5-amine 
• 1616598-88-9 C₂₀H₂₃N₅O₅ 
• 1616598-91-4 {5-[(2,4-dimethoxybenzyl)amino]-7-methoxy[1,2,4]triazolo[1,5-c]quinazolin-2-yl}methanol 
• 124309-70-2 N-benzyl-2-chloro-8-methoxy-quinazolin-4-amine 

Relevant articles and documents

ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY

The present invention provides compounds of the structural Formula (I) and pharmaceutically acceptable salts thereof, wherein, are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES

Disclosed are compounds having the structure of Formula I, or a pharmaceutically acceptable salt of any thereof: wherein: "Z" and R1 are defined herein, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.

BICYCLIC DERIVATIVE CONTAINING PYRIMIDINE RING, AND PREPARATION METHOD THEREFOR

The present invention provides: a bicyclic derivative comprising a pyrimidine ring, or a pharmaceutically acceptable salt thereof; a preparation method therefor, a pharmaceutical composition comprising the same; and a use therefor. According to the present invention, the bicyclic compound derivative comprising a pyrimidine ring, or a pharmaceutically acceptable salt thereof acts as a 5-HT4 receptor agonist, and thus can be usefully applied to the prevention or treatment of dysfunction in gastrointestinal motility, for example, gastrointestinal diseases such as gastroesophageal reflux disease (GERD), constipation, irritable bowel syndrome (IBS), dyspepsia, post-operative ileus, delayed gastric emptying, gastroparesis, intestinal pseudo-obstruction, drug-induced delayed transit, diabetic gastric atony and the like.